Search CRDF
Cardiff Oncology, Inc.
Nasdaq · CIK 1213037
Last close1.12
Daily change-0.06 (-5.08%)
10 Years gain-99.65%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CRDF · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
39.4Momentum
0.0Acceleration
0.0Confidence
89.0Annual Revenue15
Quarterly Revenue59
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.8 / 25
Quality8.6 / 25
Capital Efficiency2.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 4890.2902 percentage points.
ROIC declining · MEDIUMROIC declined by 405.4381 percentage points.
Key Metrics
Revenue Growth TTM-39.88%OK
Revenue CAGR 3Y15.39%OK
Gross Margin100%OK
Operating Margin-12,750.26%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-1,095.85%OK
Incremental Operating Margin 3Y-20,614.93%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.82%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $593,000.00 | $593,000.00 | -$48.96M | -$37.92M | -$37.97M | 100% | -8,256.32% | -6,402.53% | n/a | 66.84M |
| 2025 FY Dec 31, 2024 | $683,000.00 | $683,000.00 | -$48.65M | -$37.69M | -$37.77M | 100% | -7,123.13% | -5,530.45% | n/a | 47.65M |
| 2024 FY Dec 31, 2023 | $488,000.00 | $488,000.00 | -$45.41M | -$30.89M | -$31.47M | 100% | -9,305.74% | -6,448.57% | n/a | 44.68M |
| 2023 FY Dec 31, 2022 | $386,000.00 | $386,000.00 | -$39.90M | -$33.82M | -$34.83M | 100% | -10,337.31% | -9,022.28% | -9,381.72% | 43.6M |
| 2022 FY Dec 31, 2021 | $359,000.00 | $359,000.00 | -$28.86M | -$23.04M | -$23.25M | 100% | -8,037.6% | -6,474.93% | n/a | 39.03M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $386,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-344545, 0001193125-25-269424 |
| Revenue Growth TTM | -39.88% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-344545, 0001193125-25-269424 |
| Revenue CAGR 3Y | 15.39% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-067464 |
| Revenue CAGR 5Y | 10.13% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-067464 |
| Gross Profit CAGR 3Y | 15.39% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-067464 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-344545, 0001193125-25-269424 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-344545, 0001193125-25-269424 |
| Operating Margin | -12,750.26% | Operating Income / Revenue | OK | 0001193125-26-344545, 0001193125-25-269424 |
| ROIC | -1,095.85% | NOPAT / Average Invested Capital | OK | 0001193125-26-344545, 0001193125-25-269424 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-344545 |
| Current Ratio | 3.3x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.01 | Revenue / Diluted Shares | OK | 0001193125-26-344545, 0001193125-25-269424 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |